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Cultured human keratinocytes and artificial dermal equiva-
lents maintained in vitro do not perfectly mimic the terminal 
differentiation patterns and response to drugs observed in 
intact human skin. We have made use of human skin grafted 
onto nude mice to demonstrate that such grafts maintain the 
pattern of pharmacologic responsiveness to all-trans retinoic 
acid previously reported in human subjects. The use of a 
C ongenitally athymic (nude) mice accept xenografts of skin from a wide variety of species, including human [1- 3] . These grafts remain viable for extended peri-ods of time and have been characterized in terms of morphology and permeability [4,5] . The human 
skin- grafted nude mouse is thus a useful model system for the study 
of a variety of derma to logic phenomena, including the effects of 
topical application of pharmacologically active compounds. How-
ever, the use of such grafts to evaluate potential clinical efficacy of 
compounds has been limited so far by the small size of the grafts and 
a lack of quantitative measures of skin responsiveness. To overcome 
these limitations, we developed a quantitative polymerase chain 
reaction (PCR) method to assess the level of expression of a particu-
lar target gene [6]. The PCR method requires less than 200 ng of 
total RNA for each determination, an amount easily obtainable 
from punch biopsies or small ski~ g.raf~s. With this technique, the 
potential usefulness of the model IS slgruficantly expanded. To eval-
uate the effectiveness of our technique, we studied the pharmaco-
logic response of human skin to all-trans retinoic acid (RA). 
RA is an important modulator of cell growth and differentiation. 
Retinoid drugs have been used both systemically and topically in the 
treatment of a variety of epidermal disorders, including photoda-
mage, psoriasis, acne, and carcinoma [7 -10]. The efficacy of reti-
noids in skin is presumed to be due to the influence of RA on 
epidermal differentiation and proliferation [11]. The histologic 
changes associated with topical retinoic acid treatment of skin in-
clude epidermal hyperplasia and compaction of the stratum cor-
neum [12]. RA is known to influence the expression of a number of 
markers of keratinocyte differentiation (including loricrin, filag-
grin, epidermal transglutaminase, involucrin, and keratins 6 and 13 
[13, 14J) and to markedly increase the expression of cytoplasmic 
retinoic acid binding protein II (CRABPII), a binding protein sub-
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quantitative polymerase chain reaction method to measure 
induction of a retinoic acid responsive gene, cytoplasmic ret-
inoic acid binding protein II, has made it possible to generate 
objective data suitable for investigations of drug efficacy. 
This method of using grafted human skin has potential broad 
applicability for investigation of topical drugs in a number of 
therapeutic fields. J Invest Dermatol1 02:515 -518, 1994 
type specific to skin [15 ,16] . Recently, measurements of the steady-
state levels of CRABPII mRNA have been proposed as a selective 
marker for cutaneous retinoid activity in vivo [6,16-18]' 
The effects of RA on human skin have been previously studied 
using epidermal (keratome) biopsies from human volunteers treated 
with retinoids. Cultured keratinocytes or dermal fibroblasts have 
been of limited usefulness because the response of markers in cul-
tured cells often contrasts sharply with data from studies on intact 
skin [13,19,20] . To overcome this disparity, and to allow collection 
of data on human tissue without treating human volunteers, we felt 
the development of the human skin - grafted nude mouse model 
was particularly appropriate. 
MATERIALS AND METHODS 
Skin Transpl~ntation Nude mice (Balb/C, male and female) at 6 weeks 
old were obtamed from Charles River Inc. and kept in a pathogen-free 
colony. MI~e were anesthetized by intraperitoneal injection with tribro-
moethanolm tertiary amyl alcohol (Avertine) as described [21] . For human 
skin (1 X 1 cm) to be grafted onto the mouse body, a.graft bed of similar size 
at the upper left shoulder of the mouse was prepared by removing the 
full-thickness skm down to the fascia. Full-thickness human breast skin 
grafts (obtained with patient consent and approval of the administration of 
York-Finch General Hospital, Toronto) were either dermatomed or sliced 
out manually. The subcutaneous tissue was removed. Human skin grafts 
were then placed on the graft bed and held in place with a petroleum-gel 
coated Band-Aid wrapped around the circumference of the mouse thorax. 
The Band-Aid was stapled on the ventral side of the mouse. For small skin 
sections to be grafted onto the mouse tails, mouse skin (3 X 10 mm) near the 
base was carefully peeled off with the aid of a scalpel blade to avoid bleeding. 
Human skin of similar size was then placed over the graft site, lightly sprayed 
with liquid Band-aid, and protected with a plastic tube taped in place. Band-
Aids or tubes were removed after 7 -1 0 d and grafts were allowed to heal for 
an additional 1 - 2 weeks before drug treatment. 
Experimental Protocols Fully healed grafts were treated once daily for 
4 d with 15 ,ul of70% ethanolj30% propylene glycol vehicle containing the 
indicated concentration of all-trans RA (Sigma). Mice were sacrificed on day 
5 and the grafts removed for analysis. A 2 X 10 mm slice through the full 
thickness of each graft was transferred to OCT freezing compound and 
frozen for later histologic analysis. The remainder of the grafted tissue was 
used for RNA preparation. In the case of smaller grafts on the tail site, 5 ,ul of 
drug solution was applied and the entire graft used for either histologic 
examination or RNA preparation. 
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Histologic and Immunohistochemical Staining Serial 5-)1m sections 
were cut from both frozen and paraformaldehyde-fixed/paraffin-embedded 
tissue. For routine histologic examination, paraffin sections were dewaxed 
and hydrated through several washes of toluene and graded e~hanols, fo l-
lowed by staining with hcmatoxylll1-eosll1 .. Immuno~lstochem.lcal met!lOds 
were used to detect various markers of epidermal differentiation In either 
paraffin-fixed or frozen sections. Paraffin-fixed sections [22] were dig.ested 
10 min with pepsin and Il1cubated for 2 h with mouse monoclonal antibod-
ies against human K~O (ESBE Laboratories, dilut~d 1/200) or K13 (Bio-
genex Laboratories~ diluted 1/20) or with human-ll1volucnn specific. rabbit 
antiserum (Biomedical Technologies Inc., diluted 1/4) followed by blOtlny-
lated goat anti-rabbit IgG (Zymed, 1/200 dilution, 30 min) and streptavi-
din-conjugated horse radish peroxidase (Dako, 1/300 dilution, 30 min) and 
stained with 3-amino-9-ethyl-carbazole. Epidermal transglutaminase and 
filaggrin expression was examined in frozen sections [23] incubated with 
mouse monoclonal antibodies specific for human keratinocyte transgluta-
minase (Biomedical Technologies Inc., pre-diluted, 2 h incubation) or 
human filaggrin (Biomedical Technologies Inc., 1/1000 dilution, over-
night at 40 C) followed by biotinylated goat anti-mouse IgG (Zymed, 1/200, 
30 min) and streptavidin-conjugated alkaline phosphatase (Dako, 1/200,30 
min), and stained with New Fuschin. All antibody incubations were at room 
temperature unless otherwise stated. 
Quantitative Analysis RNA was prepared from pulverized, frozen skin 
using the method of Chomczynski and Sacchi [24]. Human RNA from 
grafted skin was quantitated relative to an RNA sample from non-grafted 
human skin by measurement of trichloroacetic acid (TCA)-precipitable 
counts generated in a reverse-transcriptase reaction using human-specific 
primers for glycerol 3-phosphate dehydrogenase (G3PDH). The sequence 
of the human G3PDH primer used in the RT -TCA precipitation analysis is 
5'-CATGTGGGCCATGAGGTCCACCAC (Clonetech). Briefly, 1)11 of 
RNA was reverse transcribed in a 20)11 reaction as described previously [6] 
with the exception that 5 )1Ci oP2P-dCTP was used to label the synthesized 
cDNA. Five microliters of the resulting mixture was added to 300 )11 of 4 
mg/ml herring sperm DNA (carrier) and precipitated with 3 ml of cold 5% 
TCA (w Iv). Precipitated cDNA was collected on a Whatman 934 AH glass 
fiber filter, washed extensively with cold 95% ethanol and the amount of 
incorporated radioactivity determined by liquid scintillation counting. All 
reactions were carried out in triplicate. The amount of human RNA within 
the graft preparations was quantitated relative to a sample of control human 
skin RNA whose concentration was known. Quantitative RT-PCR for 
human CRABPII RNA was carried out as described [6]. A human CRABPII 
specific primer (5'-CAGTGAAGCAGGGCGGTGAGCAT [CRB-4]) was 
used for the RT reaction to ensure that only human mRNA could serve as a 
template for the reaction. The primers used for the PCR step were CRB-1 
(S'-GGCAACTGGAAAATCATCCGATCGGAAAAG) and CRB-2 (5'-
CACTCTCCCATTTCACCAGGCTCTTACAG); these primers are 
96% and 93% identical to the corresponding mouse cDNA sequences and 
are not capable of distinguishing between mouse and human cDNA under 
our PCR conditions. 
RESULTS 
Skin Grafts Full-thickness human skin was obtained from three 
patients during the de-epithelialization stage of reduction mam-
mography. Two methods of skin grafting were used, both yielding 
similar results. Grafts of 1-2 cm2 were placed on the back of the 
mouse. Smaller grafts (about 0.5 cm2) placed at the base of the tail 
were sometimes used with similar results. Successful grafts were 
obtained in over 70% of mice transplanted. Graft failures were of 
technical origin, never resembling the rypical course of immuno-
logic rejection characteristic of non-immunodeficient mice. The 
graft/mouse junction was easy to identify visually by the greater 
thickness and different pigmentation of human skin. 
Histologic Analysis Detailed histologic analysis ;as carried out 
on 16 independent grafts plus a sample of non-grafted skin, all 
derived from a single patient. The grafts were divided into four 
groups and treated with vehicle (ethanol/propylene glycol), 0.01 % 
RA, 0.03% RA, or 0.10% RA. No outward sign of biologic activiry, 
such as erythema or scaling, was noticeable in any treatment groups. 
Upon completion of treatment, mice were sacrificed by cervical 
dislocation and grafts were removed for routine histologic staining 
and immunohistochemistry. Figure 1 illustrates representative sec-
tions immunostained for involucrin (A) and epidermal transgluta-
minase (B). Grafted human skin treated with vehicle alone exhib-
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Figure 1. Immunolocalization of epidermal differentiation markers in 
grafted skin. A . Immunoperoxidase staining with monoclonal antibody 
against human Lnvolucrin in grafts treated with vehicle (top), 0.1 % RA 
(center), and 1.0% RA (bottom). B. Immunoperoxidase staining with mono-
clonal antibody against human epidermal transglutaminase in grafts treated 
with vehicle (top), 0.1% RA (cwter), and 1.0% RA (bottom) . Note the 
membrane localization as indicated by the basket-weave pattern of staining. 
Control experiments indicated that mouse epidermis was not stained with 
either of these reagents. Bar, 50 )1m. 
ited a normal morphologic appearance, with preservation of rete 
ridges and a stratified pattern of epidermal differentiation (basal, 
spinous, and granular layers, as well as stratum corneum) that was 
indistinguishable from histologic samples of non-grafted human 
breast skin derived from the same individual (data not shown). 
Mouse and human epidermis could readily be distinguished by dif-
ferences in structure and thickness. The RA-treated skin graft ex-
hibited the expected histologic changes associated with topical RA 
treatment: compacting of the stratum corneum, epidermal thicken-
ing, and parakeratosis, evident even at the lowest concentration 
tested [13]. 
Markers of epidermal differentiation were also examined in skin 
grafts using immunocytochemical analysis. These included keratins 
Ki0 and K13, cornified envelope proteins involucrin and filaggrin, 
and epidermal transglutaminase (transglutaminase K, a membrane-
bound, keratinocyte-specific trans glutaminase responsible for cross-
linking of the envelope proteins). Previous studies have shown that 
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Figure 2. Levels of CRABPII mRNA in .grafted skin .. Skin grafts were 
treated dai ly for 4 d wIth vehtele aJone or wIth RA at the mdlcated concen-
trations. Grafts were excised following treatment and human CRABPII 
1l1RNA was quantitated within the treated graft tissue using the RT-PCR 
technique. Data is presented as mean of n grafts; error bars, SD. CRABPII 
mRNA levels were significantly higher in grafts treated with 0.3% RA and 
1.0% RA (p less than 0.05 with respect to vehicle, one-sided Dunnett's test). 
involucrin, filaggrin, and transglutaminase expression patterns are 
al tered in vivo by RA treatment, whereas K10 is unchanged [13,20]. 
K13, normally present only in non-keratinized epithelia, was re-
ported to be focally expressed in the suprabasallayers of epidermis in 
a small number of patients [13] . 
With these epidermal differentiation markers, we showed that 
grafted human skin exhibited responses similar to those described in 
human subjects treated with topical RA [13]. K10 was unchanged 
and no specific K13 staining was found in any of the samples tested 
(data not shown). In contr~st, a dramat~c increase of im:,olucrin 
expression was observed (FIg 1A); tillS ll1cr~ased expressIOn .was 
already maximal at the lowest RA concentratIOn tested. In velucle-
treated skin grafts, involucrin is localized in a narrow band just 
below the stratum corneum, whereas in RA-treated grafts, involu-
crin staining extended downwards, all the way to the basal layer. 
Similarly, transglutaminase K staining (Fig 1B) in vehicle-treated 
skin was found in a compact band immediately below the stratum 
corneum. RA treatment resulted in increased expression down-
wards such that the granu lar and part of the spinous layer became 
posi tively stained. The increased expression remained restricted to 
the cell membrane. Immunohistochemical staining for fila ggrin 
showed a similar expansion (data not shown). Filaggrin and transg-
lutaminase expression patterns did not extend to the basal layer as 
invo lucrin did. 
Quantitative Analysis Quantitative evaluation of the effects of 
RA treatment on the grafted skin was obtained using a quantitative 
reverse transcriptase (RT) polymerase chain reaction method devel-
oped in our laboratory to measure the induction of the RA-inducible 
marker, CRABPII [6]. Figure 2 illustrates the results of quantitative 
RT -PCR analysis of21 skin grafts derived from three patients. The 
level of CRABPII mRNA in vehicle-treated grafts ranged from 2,4 
to 26 attomoljJ.lg with a mean of 12.8 attomoljJ.lg. Data on the 
abso lute level of CRABPII mRNA in human skin biopsies has been 
published on three .subjects, and ranged fro~ 15 to 25 attomoljJ.lg 
[6]. Skin treated WIth 0.01 % RA had essentIally the same level of 
CRABPII mRNA (10.8 ± 6.6 attomoljJ.lg [mean ± SO]) as vehi-
cle-treated skin (12.8 ± 9.3 attomol/J.lg). Treatment of grafted skin 
with two higher concentrations ofRA (0.03, 0.1 %) induced a statis-
tically significant increase in CRABPII mRNA (p < 0.05 with re-
spect to vehicle, using one-sided Dunnett's test) . The difference in 
CRABPII mRNA levels between skin treated with 0.1 % RA 
(55.8 ± 8.3 attomol/J.lg) versus 0.03% RA (39.8 ± 11.3 attomolj 
J.lg) was not statistically significant. The 4,4-times induction of 
C RABPII in 0.1 % RA-treated grafts relative to vehicle-treated 
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grafts is in agreement with the range reported for human subjects 
[6 ,15,19]. Ethanol/propylene glycol vehicle has been established 
to exert no significant effect on CRABPII expression in human 
skin [1 8] . 
DISCUSSION 
The histologic and immunohistochemical analyses carried out in 
this study demonstrated that human skin grafts on nude mice re-
spond to topical RA in a fash ion similar to skin of human volunteers. 
Transglutaminase K, keratins K1, KlO, and K14, loricrin, and filag-
grin are suppressed by RA in keratinocytes cultured on plastic or 
dermal substrates, whereas involucrin and CRABPII are unaffected 
[14,19,20]' When these markers were examined in intact skin 
treated with RA [13] , it was reported that K1, K10, and K14 were 
unchanged whereas loricrin, filaggrin, involucrin, transglutaminase 
K, and CRABPII were all increased. Evaluation of RA's effects on 
K10, K13, involucrin, filaggrin, and transglutaminase K in grafted 
human skin on nude mice demonstrated that the grafts invariably 
mimic the response of intact human skin rather than keratinocytes 
cultured on plastic or dermal substrates. Two major differences be-
tween cultured keratinocyte models and ;,'1 vivo experiments are 1) 
keratinocytes in intact skin interact with the complex network of 
epidermal and dermal components, and 2) intact skin presents a 
barrier through which drug must penetrate. The precise concentra-
tion of RA reaching keratinocytes in intact skin has not been mea-
sured in published reports. However, the fact that the changes in 
expression of RA markers differ in direction and not just in extent 
suggests that keratinocyte interactions with other skin components 
is the key factor determining the nature of the response. 
To demonstrate further the usefulness of such grafts for evaluat-
ing drug effects in human skin, we made use of a quantitative RT-
PCR technique. T his method is useful to quantify a specific mRNA 
from sub-microgram amounts of total RNA obtained from punch 
biopsies or small skin grafts. In these studies, the RA-inducible 
marker CRABPII was quantitated from skin grafts treated with 
various doses of RA. 
Our quantitative RT-PCR method makes use of an internal stan-
dard consisting of a synthetic RNA generated by in vitro transcrip-
tion from a CRABPII cDNA construct containing a small deletion 
in the coding region. A concern in analysis of RNA from skin grafts 
is the contribution of mouse cells to the healed grafts. It is known 
that the vascular tissue within such grafts becomes progressively 
colonized by mouse cells [4]. Total RNA isolated from the grafts 
may contain both human and mouse RNA. Several precautions 
were taken to ensure that the RT-PCR quantitation of CRABPII 
mRNA refl ected levels of human mRNA only. The primer used 
in the RT reaction was chosen to be specific only for human 
CRABPII. Specificity was confirmed by demonstrating that the RT 
and PCR primer combination did not amplify CRABPII mRNA 
from mouse skin. Furthermore, the total human RNA concentra-
tion in preparations of total RNA from grafted skin was determined 
relative to a standard human RNA by assaying incorporation of 
nucleotide triphosphates (NTPs) in an RT reaction using a human-
specific primer for G3PDH. This primer did not result in the incor-
poration of significant levels of radioactive NTPs when mouse 
RNA was used as a substrate. 
With the quantitative PCR method, target genes induced in skin 
can be measured using punch biopsy-size skin samples, in contrast to 
standard techniques (Northern blots, RNase protection) , which re-
quire large keratome biopsies. Furthermore, the absolute level of 
mRNA present as well as the fold induction can be measured. In our 
case, the RT-PCR method was applied to a group of skin grafts 
originally derived from three reduction mammography patients; 
the fold induction of the target gene was in good agreement with 
levels measured using the other methods. The human skin grafted 
nude mouse model described here required higher concentrations of 
RA to induce CRABPII than reported recentl y in a detailed study by 
Elder et aJ in which human volunteers were treated with 0.1 % RA 
on buttocks skin for up to 4 d [1 8]. The difference is most likely due 
to the use of occlusion in the human study, which greatly increases 
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drug penetration. The absolute levels of C~PII mRNA expres-
sion in grafts (2.4 to 26 attomol/J.L~) a~e sl~11llar to data we have 
previously reported from human skm blOpsles (15 to 25 attomol/ 
J.Lg) and cultured fibroblasts .(24 attomol/J.Lg) [6] . Tl?e low v.alue 
in the grafted-skin range derives from grafts from a smgle patlent, 
who may express unusually low levels of CRABPII mRNA; grafts 
from the remaining two subjects contained 12 to 26 attomol/J.Lg 
CRABPII mRNA. 
The human skin graft model system has potential for use in a 
broad spectrum of pharmacologic applications. It is possible, using 
this method, to generate many grafts from skin derived from a 
single individual and thus test a variety of different drugs or drug 
concentrations on skin from a single individual, which is usually not 
possible on human volunteers due to ethical considerations. Human 
skin grafts have previously been used to examine wound healing 
[25,26] and hair growth (in response to cyclosporin [27]). Results in 
such studies were obtained in a semi-quantitative fashion (scar for-
mation, counts of growing hairs). As we demonstrated, quantitative 
PCR analysis is ideally suited for quantifying drug efficacy if suit-
able markers of drug action can be found; for example, measure-
ments of growth factor receptor levels may be relevant markers for 
wound healing. One other therapeutic area that might benefit from 
such a model system is study of the modulation of the inflammatory 
response. Tumor necrosis factor and interleukin-1 treated grafts 
have been assayed for leukocyte migration and induction of immu-
noreactivity for endothelial cell adhesion molecules [28]. Quantita-
tive PCR for adhesion molecules or cytokines could generate addi-
tional data in the above system. 
The model system described makes it possible to produce a useful 
in vivo viable human skin model without resorting to a transgenic 
mouse design. The potential clinical efficacy of pharmacologic 
agents (such as RA) on human skin can be evaluated with fewer 
ethical considerations compared to testing with human volunteers. 
Such grafts may also prove useful for the evaluation of the penetra-
tion of drugs in different formulations to optimize drug delivery 
before undertaking clinical trials. 
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